addiction – mycolab.ai

Neuroprotective effects of psilocybin in a rat model of stroke

mycolabadmin

Scientists studied whether psilocybin, the active compound in magic mushrooms, could protect the brain from stroke damage in rats. They found that psilocybin reduced brain damage, improved movement and behavior recovery after stroke, and worked by increasing a protective brain chemical called BDNF. This research suggests psilocybin could become a new treatment for stroke patients, especially since stroke often leads to depression and anxiety, which psilocybin may also help treat.

Synergistic, multi-level understanding of psychedelics: three systematic reviews and meta-analyses of their pharmacology, neuroimaging and phenomenology

mycolabadmin

This comprehensive study analyzed three classic psychedelic drugs—LSD, psilocybin (from magic mushrooms), and DMT—across three levels: how people experience them, how they affect brain activity, and how they interact with brain receptors. Researchers found that LSD produces more intense visual experiences than psilocybin, and all three drugs significantly alter brain connectivity patterns. The study highlights the importance of standardizing research methods to better understand how these compounds might help treat depression and addiction.

Meditation, psychedelics, and brain connectivity: A randomized controlled resting-state fMRI study of N,N-dimethyltryptamine and harmine in a meditation retreat

mycolabadmin

Researchers studied how meditation combined with a psychedelic compound called DMT affects the brain. They scanned 40 experienced meditators before and after a 3-day retreat, with some receiving the psychedelic and others a placebo. While meditation alone reduced connections between different brain networks, the psychedelic enhanced certain connections, suggesting the two practices may complement each other in promoting mental health.

Virtual reality and psychedelics: new perspectives and new possibilities in the treatment of alcohol use disorder

mycolabadmin

This article discusses how virtual reality technology that simulates psychedelic experiences could improve treatment for alcohol addiction. Virtual reality simulations can mimic the brain effects of psychedelics like psilocybin, and could help prepare patients for treatment, extend its benefits, or even work as a standalone therapy. This innovation could make psychedelic-assisted therapy more accessible and easier to standardize across different treatment centers.

Psychedelics and Neuroplasticity: A Systematic Review Unraveling the Biological Underpinnings of Psychedelics

mycolabadmin

This review examines how psychedelic substances like psilocybin and LSD affect brain structure and function. Research shows these compounds can increase BDNF (a protein crucial for brain health) and promote the growth of new neurons and connections between brain cells. These biological changes may explain why psychedelics have shown promise in treating depression and anxiety, with effects lasting weeks after a single dose.

Cystathionine Gamma-Lyase Regulate Psilocybin Biosynthesis in Gymnopilus dilepis Mushroom via Amino Acid Metabolism Pathways

mycolabadmin

Researchers studying the ‘magic mushroom’ Gymnopilus dilepis discovered that a specific enzyme called CTH plays a crucial role in producing psilocybin, the compound with potential antidepressant effects. By blocking this enzyme, they reduced psilocybin production, but adding a related compound called L-cysteine restored it. This finding suggests that controlling amino acid metabolism could help increase psilocybin production for medical use.

Biological studies of clavine alkaloids targeting CNS receptors

mycolabadmin

This paper reviews clavine alkaloids, a class of natural compounds from ergot fungi that show promise as psychiatric medications. Unlike well-known psychedelics like LSD, clavine alkaloids may provide therapeutic benefits for anxiety and depression without strong hallucinogenic effects. The authors highlight how these compounds interact with brain receptors in ways that could make them safer and more effective medications for treating mood and neurological disorders.

Palliative care patients’ attitudes and openness towards psilocybin-assisted psychotherapy for existential distress

mycolabadmin

A study asked 31 palliative care patients about their views on using psilocybin (a compound from magic mushrooms) as a treatment for existential distress—the emotional and spiritual suffering that comes with terminal illness. Over half the patients were interested in trying this therapy, especially if they believed it could help with anxiety and stress. However, patients were concerned about risks like psychosis, the lack of trained therapists, and the potential for doctors to take advantage of them during treatment. The researchers concluded that while psilocybin-assisted therapy shows promise, there needs to be better education and strict safeguards to protect vulnerable patients.

Anhedonia: Current and future treatments

mycolabadmin

Anhedonia is the inability to feel pleasure from activities, which is a significant problem affecting many people with depression and other psychiatric conditions. This review examined many different treatments for anhedonia including medications, brain stimulation techniques, and psychological therapies. The research shows that newer medications like vortioxetine and ketamine work better for anhedonia than older antidepressants, and combining multiple approaches including therapy and lifestyle changes gives the best results.

Norpsilocin: freebase and fumarate salt

mycolabadmin

Researchers determined the crystal structures of norpsilocin, a naturally occurring compound found in magic mushrooms that is chemically similar to psilocin. This work is important because norpsilocin appears to be as potent as psilocin at serotonin receptors and may contribute to the therapeutic effects of magic mushroom extracts. By obtaining pure crystalline forms and understanding the compound’s structure, scientists can better study its properties and potential medical applications for treating conditions like depression and anxiety.

Disease: addiction